These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22357407)

  • 1. Psychological aspects of active surveillance.
    van den Bergh RC; Korfage IJ; Bangma CH
    Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prostate cancer Research International: Active Surveillance study.
    Bangma CH; Bul M; Roobol M
    Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 5-alpha-reductase inhibitors in active surveillance.
    Margel D; Fleshner N
    Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    van den Bergh RC; Essink-Bot ML; Roobol MJ; Schröder FH; Bangma CH; Steyerberg EW
    J Urol; 2010 May; 183(5):1786-91. PubMed ID: 20299064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance: oncologic outcome.
    Venderbos LD; Bokhorst LP; Bangma CH; Roobol MJ
    Curr Opin Urol; 2013 May; 23(3):268-72. PubMed ID: 23425994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and disease factors affecting the choice and adherence to active surveillance.
    Dall'Era MA
    Curr Opin Urol; 2015 May; 25(3):272-6. PubMed ID: 25692724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.
    Davison BJ; Oliffe JL; Pickles T; Mroz L
    Oncol Nurs Forum; 2009 Jan; 36(1):89-96. PubMed ID: 19136342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and follow-up strategies for patients on active surveillance.
    Dall'Era MA; Carroll PR
    Curr Opin Urol; 2009 May; 19(3):258-62. PubMed ID: 19295434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
    Venderbos LD; van den Bergh RC; Roobol MJ; Schröder FH; Essink-Bot ML; Bangma CH; Steyerberg EW; Korfage IJ
    Psychooncology; 2015 Mar; 24(3):348-54. PubMed ID: 25138075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of active surveillance for prostate cancer.
    Pan DL; Samavedi S; Eldefrawy A; Manoharan M
    Postgrad Med; 2012 May; 124(3):50-8. PubMed ID: 22691899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer.
    Davison BJ; Goldenberg SL
    BJU Int; 2011 Dec; 108(11):1787-93. PubMed ID: 21507187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D; Lindner A; Stay K; Zisman A
    Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
    Albertsen P
    Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance.
    Bellardita L; Rancati T; Alvisi MF; Villani D; Magnani T; Marenghi C; Nicolai N; Procopio G; Villa S; Salvioni R; Valdagni R
    Eur Urol; 2013 Jul; 64(1):30-6. PubMed ID: 23357351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living with untreated prostate cancer: predictors of quality of life.
    Bellardita L; Villa S; Valdagni R
    Curr Opin Urol; 2014 May; 24(3):311-7. PubMed ID: 24637318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.